ANTX has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
ANTX has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
AN2 Therapeutics has the GF Value Rank of 0.
The GF Value Rank is determined by the price-to-GF-Value (P/GF Value) ratio, a proprietary metric calculated based on historical multiples along with an adjustment factor based on a company's past returns and growth and future estimates of the business' performance.
GuruFocus found that for valuation, we cannot simply give stocks a better GF Value rank simply because they have a lower P/GF Value ratio. Backtesting shows that over the long term, the two worst-performing groups are the most expensive group (with the highest P/GF Value ratio) and the least expensive group (with the lowest P/GF Value ratio).
We can understand why the most expensive group underperforms. We were initially puzzled by the underperformance of the least expensive group, but we realized there is a reason why some stocks are super cheap. If they look too undervalued, it is often because the businesses behind them are poor quality. The market realized this and gave them low valuations. In a way, the market is efficient.
After multiple backtesting analyses, we granted the stocks in third-cheapest percentile the highest GF Value rank, as they have performed the best over a full market cycle. Stock performance is actually not as sensitive to valuation as it is to growth and profitability. On average, the companies in the 20%-50% valuation groups have similar performances. Therefore, we should avoid the most expensive and the least expensive stocks. We can be more tolerant of valuation.
Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.
Thank you for viewing the detailed overview of AN2 Therapeutics's GF Value Rank provided by GuruFocus.com. Please click on the following links to see related term pages.
Joseph S Zakrzewski | director | 509 WATERVIEW PLACE, NEW HOPE PA 18938 |
Kabeer Aziz | director | 376 MANHATTAN AVENUE APT. 3, BROOKLYN NY 11211 |
Adjuvant Global Health Technology Fund De, L.p. | 10 percent owner | C/O ADJUVANT CAPITAL, L.P., 501 FIFTH AVENUE, SUITE 1404, NEW YORK NY 10017 |
Robin Shane Readnour | director | 3835 CLEGHORN AVENUE, SUITE 300, NASHVILLE TN 37215 |
Kevin Michael Krause | officer: Chief Strategy Officer | 369 27TH STREET, SAN FRANCISCO CA 94131 |
Eric Easom | director, officer: Chief Executive Officer | 171 FOREST LN., MENLO PARK CA 94025 |
Ra Capital Healthcare Fund Lp | 10 percent owner | 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116 |
Joshua M Eizen | officer: See Remarks | 3023 MONTBRETIA WAY, SAN RAMON CA 94582 |
Margaret M Fitzpatrick | director | C/O VISTAGEN THERAPEUTICS, INC., 343 ALLERTON AVE., SOUTH SAN FRANCISCO CA 94080 |
Ra Capital Nexus Fund Ii, L.p. | 10 percent owner | 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116 |
Melvin K Spigelman | director | THE MEDICINES COMPANY, 8 CAMPUS DRIVE, PARSIPPANY NJ 07054 |
Sanjay Chanda | officer: Chief Development Officer | C/O ANACOR PHARMACEUTICALS, INC., 1020 EAST MEADOW CIRCLE, PALO ALTO CA 94303 |
Adjuvant Global Health Technology Fund, L.p. | 10 percent owner | C/O ADJUVANT CAPITAL, L.P., 501 FIFTH AVENUE, SUITE 1404, NEW YORK NY 10017 |
Michael Adrian Nazak | officer: Chief Accounting Officer | 5941 OPTICAL COURT, SAN JOSE CA 95138 |
Lucy Day | officer: Chief Financial Officer | 2032 MIDDLEFIELD ROAD, PALO ALTO CA 94301 |
From GuruFocus
By Business Wire Business Wire • 05-01-2023
By Business Wire • 11-06-2023
By Business Wire • 10-11-2023
By GuruFocusNews GuruFocusNews • 06-29-2022
By GuruFocus Research • 01-12-2024
By Value_Insider Value_Insider • 10-19-2022
By Ds*** Ds*** • 08-29-2022
By Business Wire • 11-09-2023
By GuruFocusNews GuruFocusNews • 05-10-2022
By GuruFocusNews GuruFocusNews • 05-30-2022
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.